C Marwick. Show Affiliations »
Abstract
Entities: Chemical
Mesh: See more » Drug IndustryDrug and Narcotic ControlEthicsHumansImmunosuppressive Agents/adverse effectsImmunosuppressive Agents/therapeutic useLeprostatic Agents/adverse effectsLeprostatic Agents/therapeutic useThalidomide/adverse effectsThalidomide/therapeutic useUnited StatesUnited States Food and Drug Administration
Substances: See more » Immunosuppressive AgentsLeprostatic AgentsThalidomide
Year: 1997 PMID: 9326459 DOI: 10.1001/jama.278.14.1135
Source DB: PubMed Journal: JAMA ISSN: 0098-7484 Impact factor: 56.272